ONWARD Medical Completes Private Placement Successfully
ONWARD Medical N.V., a frontrunner in the field of neurotechnology, has successfully closed a private placement that has garnered significant attention. This strategic move is aimed at enhancing their innovative therapies designed for individuals with spinal cord injuries (SCI) and other movement disabilities. The total amount raised through this private placement stands impressively at EUR 50,850,000, showcasing the robust confidence institutional investors have in ONWARD's vision and capabilities.
Advancements in Neurotechnology
As an industry leader, ONWARD Medical focuses on pioneering therapies that aim to restore movement and independence for those affected by SCI. The company's innovative approach is reflected in its development of ARC Therapy, which has achieved ten Breakthrough Device Designations from the FDA.
What is ARC Therapy?
ARC Therapy leverages decades of scientific research and clinical trials to significantly enhance the quality of life for patients. The cornerstone of their offering, the ARC-EX System, is already cleared for commercial sale in both the US and Europe. This system is poised to transform rehabilitation protocols, particularly for those aging between 18 and 75 with chronic neurological deficits.
Future Prospects and Innovations
In addition to the successful ARC-EX System, ONWARD is making strides in the development of an investigational implantable system known as ARC-IM. Designed to cater to several unmet needs, including blood pressure instability post-SCI, this device exemplifies ONWARD's commitment to addressing critical patient needs.
Integrating Technology into Rehabilitation
With the potential to enhance functionality further, ARC-IM can also be integrated with cutting-edge technology, such as brain-computer interfaces (BCI) and artificial intelligence (AI). This intersection of technology and rehabilitation signifies a new frontier in the recovery process, allowing for thought-driven movement restoration.
Strategic Commitment to Patients
Headquartered in the Netherlands, ONWARD Medical maintains a dynamic presence with its Science and Engineering Center in Switzerland and a US office located in Boston, Massachusetts. Their commitment to patient care and innovative treatments is evident through their strategic positioning within multiple international markets. The company's shares are actively traded under the ticker ONWD on Euronext Brussels and Amsterdam, while their US American Depository Receipts (ADRs) trade under the ticker ONWRY.
Media and Investor Engagement
For those interested in staying updated on ONWARD’s research and technology, they encourage you to complete a webform on their website. This way, you can receive the latest news regarding therapy availability in your specific region.
Frequently Asked Questions
What is the primary focus of ONWARD Medical?
ONWARD Medical specializes in developing neurotechnology therapies aimed at restoring movement and independence in individuals with spinal cord injuries and other movement-related disabilities.
How much funding did ONWARD raise in their private placement?
The company successfully raised EUR 50,850,000 through its recent private placement.
What is ARC Therapy?
ARC Therapy is an innovative therapeutic approach developed by ONWARD Medical, leveraging advancements in neurotechnology to improve patient recovery outcomes post-spinal cord injury.
Where can I find more information about ONWARD Medical's products?
Further details about ONWARD Medical’s products and technologies can be found on their official website, ONWD.com.
How are ONWARD's shares traded?
ONWARD Medical shares are listed on Euronext Brussels and Amsterdam under the ticker ONWD, with US ADRs trading under the ticker ONWRY.
